(Q34244446)

31 July 2017

1 reference

title

The use of cytotoxic t cells for the prevention and treatment of epstein-barr virus induced lymphoma in transplant recipients (English)

1 reference

31 July 2017

0 references

1 reference

3

Rooney CM

1 reference

31 July 2017

2

Heslop HE

1 reference

31 July 2017

1

Savoldo B

1 reference

31 July 2017

publication date

1 November 2000

1 reference

31 July 2017

1 reference

31 July 2017

volume

39

1 reference

31 July 2017

issue

5-6

1 reference

31 July 2017

page(s)

455-464

1 reference

Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428190009113376

Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190009113376

Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190009113376

EBV persistence in memory B cells in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190009113376

Epstein-Barr virus persistence and virus-associated tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190009113376

Epstein-Barr virus (EBV) induced polyclonal and monoclonal B-cell lymphoproliferative diseases occurring after renal transplantation. Clinical, pathologic, and virologic findings and implications for therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190009113376

Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190009113376

Analysis of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190009113376

Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190009113376

Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190009113376

Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naïve lung transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190009113376

B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190009113376

Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190009113376

Adoptive cellular immunotherapy for EBV lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190009113376

Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190009113376

Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190009113376

Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190009113376

Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190009113376

Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190009113376

Epstein-barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190009113376

Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190009113376

A haemorrhagic fever from the Côte d'Ivoire

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190009113376

Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190009113376

Use of rituximab and irradiated donor-derived lymphocytes to control Epstein-Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190009113376

Treatment of organ transplant-related lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190009113376

Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190009113376

Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190009113376

Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190009113376

Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190009113376

Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190009113376

Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190009113376

Feasibility of cellular adoptive immunotherapy for Epstein-Barr virus-associated lymphomas using haploidentical donors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190009113376

Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190009113376

Posttransplantation lymphoproliferative disorders in pediatric thoracic organ recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190009113376

10.3109/10428190009113376

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference